Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.643 | The Efficacy and Safety of SGLT2 Therapy in Advanced Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.163 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.363 | Modified Creatinine Index as a Non-Invasive Tool for the Monitoring of Muscle Mass in Peritoneal Dialysis |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2017.648 | Extracellular Mitochondrial DNA Released by Peritoneal Mesothelial Cell as the Trigger of Macrophage Activation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.283 | The role of Activating Transcription Factor 5 (ATF5) for mitochondrial protection in diabetic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.245 | Defining the Optimal Duration of Treatment for “Low-Risk” Peritoneal Dialysis-Related Peritonitis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.646 | Regulation of Peritoneal Transport by the Cyclooxygenase Pathway and Its Pharmacological Modulation |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.333 | A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2020.224 | Optimal Strategy for the Monitoring of Dialysis Adequacy in Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2019.363 | Intra-renal miR-21 expression in IgA nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.582 | Pharmacological Treatment of Mitochondrial Dysfunction in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.310 | Systemic absorption of oral vancomycin: prevalence, risk factors, and clinical implications |
Prof. SZETO Cheuk Chun Cheuk Chun Szeto |
| 2024.609 | Systemic Absorption of Oral Vancomycin Used for the Treatment of Clostridioides Difficile-Associated Diarrhea |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.817 | Acute Change in Kidney Function Following Concomitant Initiation of SGLT2 Inhibitors and RAAS Inhibitors: Retrospective Case Control Study |
Prof. Szeto Cheuk Chun 司徒卓俊 |
| 2025.857 | Metabolic-Dysfunction Associated Chronic Kidney Disease: Is it a Real Entity? |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.641 | Peritoneal Leukocyte Load as Predictor of Peritoneal Membrane Failure |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.385 | A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.429 | A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) | Prof. SZETO Cheuk Chun |
| 2025.834 | Elucidating the Interplay Between Myokines and Uremic Toxins in the Pathogenesis of Insulin Resistance in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.551 | Mechanisms of Podocyte Protection by Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Kidney Disease |
Prof. SZETO Cheuk Chun Cheuk Chun Szeto |
| 2025.853 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL) | Prof. SZETO Cheuk Chun |
| 2024.178 | The Efficacy and Safety of Intermittent Sodium Zirconium Cyclosilicate Therapy for the Prevention of Hyperkalemia in Chronic Kidney Disease |
Prof. SZETO Cheuk Chun Szeto Cheuk Chun |
| 2025.491 | A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.381 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.136 | Acute kidney injury in acute coronary syndrome: prevalence, risk factors, and prognosis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.315 | Discontinuation of sodium-glucose cotransporter-2 inhibitors in advanced chronic kidney disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.321 | Defining the optimal frequency of dialysis adequacy test for peritoneal dialysis patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2024.402 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2023.562 | Urinary Biomarkers for the Early Diagnosis and Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2026.584 | A Phase IIIb, multi-center, two-arm, randomized, doubleblind, parallel group study to evaluate the efficacy and safety of zigakibart and atrasentan versus zigakibart and placebo in patients with primary IgA nephropathy (LUMINA IgAN) | Prof. Szeto Cheuk Chun |
| 2026.196 | Prevalence and Prognostic Significance of the FIFA (Frailty, Inflammation, Fluid-Overload, and Atherosclerosis) Complex in Incident Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2026.193 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-Phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants with Confirmed PKD1 Mutation-Associated Autosomal Dominant Polycystic Kidney Disease | Prof. SZETO Cheuk Chun |
| 2026.361 | Personalized Peritoneal Dialysis Prescription by Early Assessment of Peritoneal Transport Status Before Home Dialysis Training |
Prof. Szeto Cheuk Chun 司徒卓俊 |
| 2026.556 | A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy | Prof. Szeto Cheuk Chun |
| 2017.368 | Urinary Sediment RNA Profile for the Prediction of Therapeutic Response in Lupus Nephritis |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.482 | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | Prof. SZETO Cheuk Chun |
| 2017.420 | Urinary miRNA profile as the biomarker of IgA nephropathy |
Prof Szeto Cheuk Chun 司徒卓俊 |
| 2015.327 | The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients with High Dialysis Effluent Bacterial DNA Fragment Levels |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.480 | Urinary RNA Levels as Prognostic Indicators of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2014.564 | Urinary Podocyte mRNA as a Prognostic Marker of Diabetic Nephropathy | Prof. SZETO Cheuk Chun |
| 2014.352 | Long Non-Coding RNA (IncRNA) in the Urinary Sediment of Patients with Chronic Kidney Disease | Professor SZETO Cheuk Chun |
| 2016.483 | Cost-effectiveness analysis of screening of BK virus-associated nephropathy using urine cytology and serum quantitative polymerase chain reaction |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2016.721 | Urinary Mitochondrial DNA Level as a Biomarker of Chronic Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.250 | Genetic Determinants of Peritoneal Transport Characteristics and Cardiovascular Diseases for Peritoneal Dialysis Patients |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2015.228 | Relation Between Peritoneal Dialysis Effluent microRNA Level and Longitudinal Change in Peritoneal Transport Characteristics |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.307 | A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2011.256 | Prospective study on lcinical predictive value of hepatitis B surface antigen for sustained virologic response to pegylated interferon in patients infected with chronic hepatitis B | Dr. SZE YUEN CHUN |
| 2010.410 | Week 24 response and long-term outcomes of lamivudine in patients with chronic hepatitis B - A prospective cohort study | Dr. SZE YUEN CHUN |
| 2024.097 | The impact of sign-phonological awareness training on language and literacy development in deaf and hearing bimodal bilingual children | Prof. SZE Yim Binh Felix |
Page 75 of 289.